Balyasny Asset Management
WVE icon

Balyasny Asset Management’s Wave Life Sciences WVE Stock Holding History

Balyasny Asset Management’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.53M Buy
+211,074
New +$2.75M ﹤0.01% 1904
2025
Q4 		– Sell
-18,427
Closed -$135K – 3619
2025
Q3 		$135K Buy
+18,427
New +$149K ﹤0.01% 2772
2024
Q2 		– Sell
-27,541
Closed -$170K – 3178
2024
Q1 		$170K Sell
27,541
-61,429
-69% -$308K ﹤0.01% 2443
2023
Q4 		$449K Buy
88,970
+52,618
+145% +$281K ﹤0.01% 1998
2023
Q3 		$209K Buy
+36,352
New +$166K ﹤0.01% 2022
2023
Q2 		– Sell
-30,154
Closed -$131K – 2864
2023
Q1 		$131K Buy
30,154
+19,369
+180% +$88.7K ﹤0.01% 2292
2022
Q4 		$75.5K Buy
+10,785
New +$49.7K ﹤0.01% 2286
2021
Q3 		– Sell
-390,104
Closed -$2.6M – 2482
2021
Q2 		$2.6M Buy
+390,104
New +$2.55M 0.01% 940
2019
Q1 		– Sell
-19,584
Closed -$823K – 1695
2018
Q4 		$823K Buy
19,584
+11,450
+141% +$509K 0.01% 956
2018
Q3 		$407K Buy
+8,134
New +$367K ﹤0.01% 1431
2017
Q3 		– Sell
-49,000
Closed -$911K – 2118
2017
Q2 		$911K Buy
+49,000
New +$1.06M ﹤0.01% 1129

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Balyasny Asset Management's WVE Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Wave Life Sciences (WVE) in Q1 2026: 211,074 shares worth $1.53M. The stake represents ﹤0.01% of the portfolio and ranks #1904 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in WVE as recently as Q3 2025.

Balyasny Asset Management first reported a position in WVE in Q2 2017 and has held it in 11 quarters since. The position peaked at $2.6M in Q2 2021. 230 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • Balyasny Asset Management held 211,074 shares of Wave Life Sciences worth $1.53M as of Q1 2026.
  • Wave Life Sciences was a new Balyasny Asset Management position in Q1 2026.
  • Wave Life Sciences made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1904 holding.
  • Balyasny Asset Management first reported a position in Wave Life Sciences in Q2 2017 and has held it in 11 quarters since.
  • Balyasny Asset Management's Wave Life Sciences position peaked at $2.6M in Q2 2021.
  • 230 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.